Optimal duration of eptifibatide infusion in percutaneous coronary intervention (An ESPRIT substudy)

Abdallah G. Rebeiz, Jean Pierre Dery, Anastasios A. Tsiatis, J. Conor O'Shea, Brent A. Johnson, Anne S. Hellkamp, Karen S. Pieper, Ian Gilchrist, James Slater, J. Brent Muhlestein, Diane Joseph, Michael M. Kitt, James E. Tcheng

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Although randomized trials have clearly demonstrated the clinical efficacy with regimens of platelet glycoprotein IIb/IIIa antagonists that result in >80% inhibition of baseline platelet aggregation in percutaneous coronary intervention (PCI), there are no data available concerning the optimal duration of infusion of these agents. In an era when the length of hospitalization has a major impact on health care costs, the determination of the optimal duration of the infusion of these drugs after PCI is of great relevance. The investigators therefore sought to determine the optimal length of the infusion of eptifibatide after PCI by analyzing the outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy trial who were randomized to treatment with eptifibatide.

Original languageEnglish (US)
Pages (from-to)926-929
Number of pages4
JournalAmerican Journal of Cardiology
Volume94
Issue number7
DOIs
StatePublished - Oct 1 2004

Fingerprint

Percutaneous Coronary Intervention
Integrin beta3
Platelet Glycoprotein GPIIb-IIIa Complex
Platelet Aggregation
Health Care Costs
Hospitalization
Blood Platelets
Research Personnel
Therapeutics
Pharmaceutical Preparations
eptifibatide

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Rebeiz, A. G., Dery, J. P., Tsiatis, A. A., O'Shea, J. C., Johnson, B. A., Hellkamp, A. S., ... Tcheng, J. E. (2004). Optimal duration of eptifibatide infusion in percutaneous coronary intervention (An ESPRIT substudy). American Journal of Cardiology, 94(7), 926-929. https://doi.org/10.1016/j.amjcard.2004.06.030
Rebeiz, Abdallah G. ; Dery, Jean Pierre ; Tsiatis, Anastasios A. ; O'Shea, J. Conor ; Johnson, Brent A. ; Hellkamp, Anne S. ; Pieper, Karen S. ; Gilchrist, Ian ; Slater, James ; Muhlestein, J. Brent ; Joseph, Diane ; Kitt, Michael M. ; Tcheng, James E. / Optimal duration of eptifibatide infusion in percutaneous coronary intervention (An ESPRIT substudy). In: American Journal of Cardiology. 2004 ; Vol. 94, No. 7. pp. 926-929.
@article{4d57a9e7a802414fac672d3db6da18b2,
title = "Optimal duration of eptifibatide infusion in percutaneous coronary intervention (An ESPRIT substudy)",
abstract = "Although randomized trials have clearly demonstrated the clinical efficacy with regimens of platelet glycoprotein IIb/IIIa antagonists that result in >80{\%} inhibition of baseline platelet aggregation in percutaneous coronary intervention (PCI), there are no data available concerning the optimal duration of infusion of these agents. In an era when the length of hospitalization has a major impact on health care costs, the determination of the optimal duration of the infusion of these drugs after PCI is of great relevance. The investigators therefore sought to determine the optimal length of the infusion of eptifibatide after PCI by analyzing the outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy trial who were randomized to treatment with eptifibatide.",
author = "Rebeiz, {Abdallah G.} and Dery, {Jean Pierre} and Tsiatis, {Anastasios A.} and O'Shea, {J. Conor} and Johnson, {Brent A.} and Hellkamp, {Anne S.} and Pieper, {Karen S.} and Ian Gilchrist and James Slater and Muhlestein, {J. Brent} and Diane Joseph and Kitt, {Michael M.} and Tcheng, {James E.}",
year = "2004",
month = "10",
day = "1",
doi = "10.1016/j.amjcard.2004.06.030",
language = "English (US)",
volume = "94",
pages = "926--929",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

Rebeiz, AG, Dery, JP, Tsiatis, AA, O'Shea, JC, Johnson, BA, Hellkamp, AS, Pieper, KS, Gilchrist, I, Slater, J, Muhlestein, JB, Joseph, D, Kitt, MM & Tcheng, JE 2004, 'Optimal duration of eptifibatide infusion in percutaneous coronary intervention (An ESPRIT substudy)', American Journal of Cardiology, vol. 94, no. 7, pp. 926-929. https://doi.org/10.1016/j.amjcard.2004.06.030

Optimal duration of eptifibatide infusion in percutaneous coronary intervention (An ESPRIT substudy). / Rebeiz, Abdallah G.; Dery, Jean Pierre; Tsiatis, Anastasios A.; O'Shea, J. Conor; Johnson, Brent A.; Hellkamp, Anne S.; Pieper, Karen S.; Gilchrist, Ian; Slater, James; Muhlestein, J. Brent; Joseph, Diane; Kitt, Michael M.; Tcheng, James E.

In: American Journal of Cardiology, Vol. 94, No. 7, 01.10.2004, p. 926-929.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Optimal duration of eptifibatide infusion in percutaneous coronary intervention (An ESPRIT substudy)

AU - Rebeiz, Abdallah G.

AU - Dery, Jean Pierre

AU - Tsiatis, Anastasios A.

AU - O'Shea, J. Conor

AU - Johnson, Brent A.

AU - Hellkamp, Anne S.

AU - Pieper, Karen S.

AU - Gilchrist, Ian

AU - Slater, James

AU - Muhlestein, J. Brent

AU - Joseph, Diane

AU - Kitt, Michael M.

AU - Tcheng, James E.

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Although randomized trials have clearly demonstrated the clinical efficacy with regimens of platelet glycoprotein IIb/IIIa antagonists that result in >80% inhibition of baseline platelet aggregation in percutaneous coronary intervention (PCI), there are no data available concerning the optimal duration of infusion of these agents. In an era when the length of hospitalization has a major impact on health care costs, the determination of the optimal duration of the infusion of these drugs after PCI is of great relevance. The investigators therefore sought to determine the optimal length of the infusion of eptifibatide after PCI by analyzing the outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy trial who were randomized to treatment with eptifibatide.

AB - Although randomized trials have clearly demonstrated the clinical efficacy with regimens of platelet glycoprotein IIb/IIIa antagonists that result in >80% inhibition of baseline platelet aggregation in percutaneous coronary intervention (PCI), there are no data available concerning the optimal duration of infusion of these agents. In an era when the length of hospitalization has a major impact on health care costs, the determination of the optimal duration of the infusion of these drugs after PCI is of great relevance. The investigators therefore sought to determine the optimal length of the infusion of eptifibatide after PCI by analyzing the outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy trial who were randomized to treatment with eptifibatide.

UR - http://www.scopus.com/inward/record.url?scp=5344272476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5344272476&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2004.06.030

DO - 10.1016/j.amjcard.2004.06.030

M3 - Article

C2 - 15464679

AN - SCOPUS:5344272476

VL - 94

SP - 926

EP - 929

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -